|
市場調查報告書
神經因性疼痛的企業簡介：對於大企業初期階段的研究費減少所伴隨的企業開發到產品導入之轉移
Key Companies: Neuropathic Pain - In-house to in-license as Big Pharma cuts down on early-stage research
| 出版商 |
Datamonitor |
| 出版日期 |
2011年10月 |
商品編碼 |
229417 |
| 內容資訊 |
英文 Pages: 40 |
| 價格 |
|
|
神經因性疼痛的企業簡介：對於大企業初期階段的研究費減少所伴隨的企業開發到產品導入之轉移 是由出版商Datamonitor在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 40 價格從美金3800起跳。
Pfizero為了守住神經因性疼痛市場的首位而努力、提供多樣化與平衡的產品線。另一方面、2011年8月的FDA承認慢性疼痛治療藥的Nucynta ER，顯示了Johnson & Johnson與Grunenthal將慢慢成為神經因性疼痛將來市場中的主要業者。
本報告書為神經因性疼痛市場之主要企業與各家產品線的SWOT分析、主要企業品牌生命週期與產品線管理戰略、神經因性疼痛領域中的活潑企業的戰略傾向與最近的認證契約之影響、對於將來性機會與課題的企業對應方法等的相關詳細調査・分析，概述如下。
第1章 總綱
第2章 概要
第3章 企業戰略
- 戰略概要
- 企業戰略的趨勢
- 無法滿足高水準的需求讓神經因性疼痛醫藥品受到更多關住
- 企業戰略中的最近變化
- 大製藥企業從初期開發階段退出，同時包含後期階段產品的往許可內契約靠攏的傾向
- 最近的戰略合作/交易
- 大製藥企業導入在許可內契約下的產品、收購小規模企業以強化神經因性疼痛管道
- Pfizer收購King是近年神經因性疼痛市場中最大的M&A活動
第4章 Pfizer
- 企業戰略
- 神經因性疼痛的產品線評價
- 取得管道藥平衡的產品線表現出對長期性神經因性疼痛的關心
- 神經因性疼痛的Pfizer產品線SWOT分析
第5章 Grunenthal
- 企業戰略
- 市場經驗與透過大規模管道、保持神經因性疼痛中的Grunenthal的將來存在感
- 神經因性疼痛產品線評價
- 為了支援使用神經因性疼痛中的阿片類藥物、Grunenthal應明確提示以減少亂用的可能性與長期性副作用
- 神經因性疼痛的Grunenthal產品線SWOT分析
第6章 其他的主要企業產品線評論
- Eli Lilly
- 從顯示出管道藥不足的神經因性疼痛市場撤退
- 剩下的地區性擴大下的千憂解取得了商業可能性
- Johnson & Johnson
- Nucynta ER將Johnson & Johnson疼痛市場中的巨大存在感擴大到神經因性疼痛領域
- Johnson & Johnson管道顯示了對神經因性疼痛領域的關注增加
- Astellas
- 排列著投資優先順序的最近市場相關企業
- 將來的市場浸透率受到Qutenza的接受與初期階段管道候補藥的發展所左右
- 其他
- 多數企業有著要滿足神經因性疼痛中未被滿足的需求的活潑管道
第7章 參考文獻
第8章 附錄
Description
Introduction
Pfizer is endeavouring to defend its market dominance in the neuropathic pain market, offering a diverse and balanced pain portfolio. Meanwhile, the August 2011 Food and Drug Administration (FDA) approval of Nucynta ER (extended release tapentadol) for the treatment of chronic pain points towards Johnson & Johnson and Grunenthal becoming key players in the future neuropathic pain market.
Features and benefits
- Identify the leading companies in the neuropathic pain market and the strengths, weaknesses, opportunities, and threats of their portfolios.
- In-depth discussion of brand lifecycle and portfolio management strategies of key companies in the neuropathic pain market.
- Assess trends in corporate strategies of companies active in the neuropathic pain arena and understand the impact of key recent licensing deals.
- Learn how companies can respond to future opportunities and challenges in the field.
Highlights
- The strong marketing platform offered by large pharmaceutical companies is necessary to penetrate the neuropathic pain sector given the fierce competition from off-label prescribing. As Big Pharma cuts early stage R&D resources and looks to in-license later stage products, smaller companies should look to such partners to bring a product to market.
- Key trends in corporate strategy include indication and geographic expansions for marketed agents in the neuropathic pain field. While improved efficacy remains the major unmet need, the development of treatments with novel mechanisms of action and different modes of delivery are all small but important steps to improve dosing convenience.
- There is mixed interest in the future market due to the high cost and complexities of neuropathic pain research. Pfizer, Grunenthal and Johnson & Johnson all have active pipelines indicating their long-term presence. Meanwhile, a lack of pipeline candidates suggests Eli Lilly and Endo are shifting away from neuropathic pain research altogether.
Your key questions answered
- How successful are the portfolio management strategies most widely used in the neuropathic pain market?
- How can emerging trends in the neuropathic pain market be exploited by leading companies to guide strategic decisions?
- What opportunities remain for Pfizer's neuropathic pain portfolio before and after Lyrica's patent expiry?
- What are the implications of Pfizer's acquisition of King Pharmaceuticals and Icagen?
- How can current and prospective players ensure longevity in the neuropathic pain market?
TOC
Executive Summary
- Strategic scoping and focus
- Datamonitor key findings
- Related reports
OVERVIEW
COMPANY STRATEGIES
- Strategic overview
- Trends in corporate strategy
- High level of unmet need drives pharmaceutical interest in neuropathic pain
- Recent shifts in corporate strategy
- Big Pharma are increasingly in-licensing later-stage products as they shift away from early-stage research
- Recent strategic partnerships/deals
- Big Pharma is in-licensing products and acquiring small firms to strengthen the neuropathic pain pipeline
- Pfizer's acquisition of King is the most notable M&A activity in the neuropathic pain market in recent years
PFIZER
- Corporate strategy
- Pfizer will defend its position as a key player in neuropathic pain market
- Neuropathic pain portfolio assessment
- Balanced portfolio of pipeline agents indicates long-term interest in neuropathic pain
- SWOT analysis for Pfizer's neuropathic pain portfolio
GRUNENTHAL
- Corporate strategy
- Market experience and sizable pipeline secures Grunenthal's future neuropathic pain presence
- Neuropathic pain portfolio assessment
- Grunenthal should demonstrate low abuse potential and long term side-effects to support opioid use in neuropathic pain
- SWOT analysis for Grunenthal's neuropathic pain portfolio
PORTFOLIO REVIEW OF OTHER LEADING COMPANIES
- Eli Lilly
- Lack of pipeline agents suggests that the company is moving away from neuropathic pain
- Geographic expansions will squeeze the last of the remaining commercial potential of Cymbalta
- Johnson & Johnson
- Nucynta ER will extend Johnson & Johnson's major pain market presence to include neuropathic pain
- Johnson & Johnson's pipeline indicates increasing interest in the neuropathic pain field
- Astellas
- Recent market entrant is prioritizing investment focus
- Future market penetration rests upon Qutenza uptake and progression of early-stage pipeline candidates
- Others
- Many companies have active pipelines in an attempt to target the unmet needs in neuropathic pain
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
APPENDIX
- PharmaVitae Explorer database
- Contributing experts
- Conferences attended
- Report methodology
|
